Annexon, Inc. (ANNX) shares are gaining more than 29 percent on Tuesday morning trade after the company announced a positive results for a phase 3 trial of C1q blocking antibody ANX005 in Guillain-Barre Syndrome. The trial met its primary endpoint with ANX005 30 mg/kg with statistically significant improvement.
Currently, ANNX is at $5.99, up 30.26 percent from the previous close of $4.58, on a volume of 36,935,980.
For comments and feedback: editorial@rttnews.com